Incyte price target raised to $67 from $64 at RBC Capital

RBC Capital raised the firm’s price target on Incyte (INCY) to $67 from $64 and keeps a Sector Perform rating on the shares after its Q1 earnings beat. The company’s commercial dynamics look generally solid, with Jakafi continuing to demonstrate good y/y volume demand and improvements in paid drug, while Opzelura – though weaker than expected – is still likely to rebound to meet guidance, the analyst tells investors in a research note.